CLINICAL TRIALS PROFILE FOR HYDROCORTISONE ACETATE
✉ Email this page to a colleague
All Clinical Trials for HYDROCORTISONE ACETATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00915343 ↗ | Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency | Completed | Shire | Phase 2/Phase 3 | 2007-08-21 | This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency |
| NCT01014364 ↗ | Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu | Terminated | Assistance Publique - Hôpitaux de Paris | Phase 3 | 2010-03-01 | The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient. |
| NCT01014364 ↗ | Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu | Terminated | University of Versailles | Phase 3 | 2010-03-01 | The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient. |
| NCT01055249 ↗ | UVB Model Validation Study | Completed | X-pert Med GmbH | Phase 1 | 2010-01-01 | Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas. |
| NCT01495910 ↗ | A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2011-12-01 | The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYDROCORTISONE ACETATE
Condition Name
Clinical Trial Locations for HYDROCORTISONE ACETATE
Trials by Country
Clinical Trial Progress for HYDROCORTISONE ACETATE
Clinical Trial Phase
Clinical Trial Sponsors for HYDROCORTISONE ACETATE
Sponsor Name
